As Senior Health Economist, Dr. Taylor works with teams to evaluate the economic consequences of health care interventions and the impact of economic interventions such as reimbursement changes on system processes, patient outcomes, and costs.
Dr. Taylor is senior evaluation lead on the CMS Innovation Center (formerly: CMMI) grant to reduce the burden of childhood dental disease in the Michigan Medicaid population. He leads the internal evaluation effort to assess the impact of the CMS project on increasing provision of preventive oral health services, reducing childhood dental disease, and evaluating its impact on health care costs. He had a similar role on an earlier CMS grant to curb inappropriate medical imaging in Southeast Michigan. Dr. Taylor also works on the data analytics team for the federally funded Great Lakes Practice Transformation Network.
Prior to joining Altarum, Dr. Taylor was senior director of advanced analytics at Health Care Service Corporation where he led the Pharmacy Analytics team responsible for evaluating program interventions and monitoring program performance. He held academic positions at Wayne State University, the University of Iowa, and Kalamazoo College where his research focused on health economics and outcomes research. He led outcomes research teams at Research Triangle Institute–Health Solutions and Pfizer. He has authored numerous publications in peer-reviewed journals and has presented his research in many professional forums.
Dr. Taylor lead research teams that evaluated the economic impact of pharmacy and pharmaceutical interventions (medication therapy management, specialty pharmacy care management programs, pneumococcal vaccines, anticoagulants, antipsychotics, disease modifying anti-rheumatic drugs). He studied the impact of electronic prescribing on pharmacy work flows and error rates and estimated the lifetime cost of stroke. He has considerable experience modeling lifetime outcomes and working with health insurance claims data including Medicare, Medicaid, and commercial claims. He led the effort to collect patient-reported quality of life measures alongside clinical trials of new medicines to treat schizophrenia, bipolar disorder, depression, anxiety disorders, and for patients requiring anticoagulants.
Dr. Taylor holds a PhD in economics from the University of Iowa and a BA in economics from the University of Minnesota, Duluth.